FDA Clears Erchonia's FX 635 for Relief of Chronic Musculoskeletal Pain

MELBOURNE, Fla., July 17, 2019 -- (Healthcare Sales & Marketing Network) -- Erchonia Corporation, the global leader in the manufacturing and development of low level laser therapy technology ("3LT"), today announces that the U.S. Food and Drug A... Devices, FDA Erchonia, low level laser therapy, FX 635, 3LT, Musculoskeletal Pain
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news